Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Trepel Website

Jane B. Trepel

Selected Publications

1)  Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M.
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.
Future Med Chem. 5: 1059-71, 2013.
2)  Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y, Hasumi H, Xu W, Fukushima H, Nakamura K, Koga F, Kihara K, Trepel J, Picard D, Neckers L.
Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.
Proc. Natl. Acad. Sci. U.S.A. 110: E1604-12, 2013.
3)  Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.
Posttranslational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Oncotarget. 4: 1065-74, 2013.
4)  Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica. 99: e81-3, 2014.
5)  Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.
Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.
Mol. Cell. 53: 317-29, 2014.
6)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 15: 191-200, 2014.
7)  Giubellino A, Shankavaram U, Bullova P, Schovanek J, Zhang Y, Shen M, Patel N, Elkahloun A, Lee MJ, Trepel J, Ferrer M, Pacak K.
High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma.
PLoS ONE. 9: e90458, 2014.
8)  Nguyen P, Lee S, Lorang-Leins D, Trepel J, Smart DK.
SIRT2 Interacts with Beta-catenin to Inhibit Wnt Signaling Output in Response to Radiation-Induced Stress.
Mol. Cancer Res. 2014.
9)  Neckers L, Trepel JB.
Stressing the development of small molecules targeting HSP90.
Clin. Cancer Res. 20: 275-7, 2014.
10)  Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer Chemother. Pharmacol. 71: 981-90, 2013.
11)  Bellon M, Ko NL, Lee M, Yao Y, Waldmann TA, Trepel JB, Nicot C.
Adult T-cell leukemia cells over-express Wnt5a and promote osteoclast differentiation.
Blood. [Epub ahead of print], 2013.
12)  Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee MJ, Nagy PL, Lee YH, Trepel JB, Beutler JA, Linehan WM, Neckers L.
Englerin A stimulates PKC? to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality.
Cancer Cell. 23: 228-37, 2013.
13)  Luger D, Yang YA, Raviv A, Weinberg D, Banerjee S, Lee MJ, Trepel J, Yang L, Wakefield LM.
Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.
PLoS ONE. 8: e76115, 2013.
14)  Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB.
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor.
J. Clin. Oncol. [Epub ahead of print], 2013.
15)  Pepe A, Pamment M, Kim YS, Lee S, Lee MJ, Beebe K, Filikov A, Neckers L, Trepel JB, Malhotra SV.
Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.
J. Med. Chem. 56: 8280-97, 2013.
16)  Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, Ying W, Neckers L, Trepel JB, Pacak K.
Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
PLoS ONE. 8: e56083, 2013.
17)  Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M, Shinohara N, Nonomura K, Neckers L.
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
Cancer Res. 73: 7022-33, 2013.
18)  Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.
Cell Cycle. 11: 3649-55, 2012.
19)  Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beebe K, Siderius M, Lee M, Couvillon A, Trepel JB, Miyata Y, Matts R, Neckers L.
Dynamic Tyrosine Phosphorylation Modulates Cycling of the HSP90-P50(CDC37)-AHA1 Chaperone Machine.
Mol Cell. 47: 434-43, 2012.
20)  Solier S, Kohn KW, Scroggins B, Xu W, Trepel J, Neckers L, Pommier Y.
Feature Article: Heat shock protein 90alpha (HSP90alpha), a substrate and chaperone of DNA-PK necessary for the apoptotic response.
Proc Natl Acad Sci U S A. 109: 12866-72, 2012.
21)  Kim YS, Kumar V, Lee S, Iwai A, Neckers L, Malhotra SV, Trepel JB.
Methoxychalcone inhibitors of androgen receptor translocation and function.
Bioorg. Med. Chem. Lett. 22: 2105-9, 2012.
22)  Alarcon SV, Mollapour M, Lee M-, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo A, Giaccone G, Xu W, Neckers LM, Trepel JB.
Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90-Targeted Therapy.
Curr Mol Med. 12: 1125-41, 2012.
23)  Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clin. Cancer Res. 17: 6831-9, 2011.
24)  Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L.
Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity.
Oncotarget. 2: 407-17, 2011.
25)  Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH.
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Eur. J. Cancer. 47: 997-1005, 2011.
26)  Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ.
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
J. Clin. Oncol. 29: 2052-9, 2011.
27)  Xu W, Trepel J, Neckers L.
Ras, ROS and proteotoxic stress: a delicate balance.
Cancer Cell. 20: 281-2, 2011.
28)  De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Sang Kim Y, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB.
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 108: 11878-83, 2011.
29)  Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA.
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Cancer Cell. 20: 315-27, 2011.
30)  Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW, Trepel JB, Prodromou C, Pearl LH, Neckers L.
Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity.
Mol. Cell. 41: 672-81, 2011.
31)  Kong HS, Lee S, Beebe K, Scroggins B, Gupta G, Lee MJ, Jung YJ, Trepel J, Neckers L.
Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Mol. Pharmacol. 78: 1072-8, 2010.
32)  Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 2070-6, 2010.
33)  Wang Y, Trepel JB, Neckers LM, Giaccone G.
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
Curr Opin Investig Drugs. 11: 1466-76, 2010.
34)  Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.
Mol. Cell. 37: 333-43, 2010.
35)  Trepel J, Mollapour M, Giaccone G, Neckers L.
Targeting the dynamic HSP90 complex in cancer.
Nat. Rev. Cancer. 10: 537-49, 2010.
36)  Sudarshan S, Sourbier C, Kong H, Block K, Romero VV, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee M, Gourlay CW, Trepel J, Linehan WM, Neckers L.
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1{alpha} stabilization by glucose-dependent generation of reactive oxygen species.
Mol Cell Biol. 29: 4080-90, 2009.
37)  Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN.
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Blood. 113: 4016-26, 2009.
38)  Tsutsumi S, Mollapour M, Graf C, Lee CT, Scroggins BT, Xu W, Haslerova L, Hessling M, Konstantinova AA, Trepel JB, Panaretou B, Buchner J, Mayer MP, Prodromou C, Neckers L.
Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain.
Nat. Struct. Mol. Biol. 16: 1141-7, 2009.
39)  Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA, Trepel JB.
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA.
J. Biol. Chem. 284: 15206-14, 2009.
40)  Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, Trepel JB.
Update on Hsp90 inhibitors in clinical trial.
Curr Top Med Chem. 9: 1479-92, 2009.
41)  Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L.
A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.
Oncogene. 27: 2478-87, 2008.
42)  Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, Schrump DS.
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Cancer Biol. Ther. 7: 1388-97, 2008.
43)  Sun L, Huang L, Nguyen P, Bisht KS, Bar-Sela G, Ho AS, Bradbury CM, Yu W, Cui H, Lee S, Trepel JB, Feinberg AP, Gius D.
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation.
Cancer Res. 68: 2726-35, 2008.
44)  Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, Hanson JT, Wong E, Buxhoeveden N, Trepel JB, Fojo AT, Telford W, Fowler DH.
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
J. Immunol. 180: 89-105, 2008.
45)  Lee M, Kim YS, Kummar S, Giaccone G, Trepel JB.
Histone deacetylase inhibitors in cancer therapy.
Curr Opin Oncol. 20: 639-49, 2008.
46)  Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, Neckers L.
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone.
Proc. Natl. Acad. Sci. U.S.A. 105: 15541-6, 2008.
47)  Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L.
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.
Leuk. Res. 32: 761-70, 2008.
48)  Chen T, Lee MJ, Kim YS, Lee S, Kummar S, Gutierrez M, Hewitt SM, Trepel JB, Levin IW.
Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation.
Anal. Chem. 80: 6390-6, 2008.
49)  Lee M, Chung EJ, Lee S, Chung J, Telford WG, Sausville EA, Gojo I, Karp JE, Gore SD, Kapoor V, Kim YS, Kummar S, Gutierrez M, Hewitt SM, Trepel JB.
A cell microarray patform for anticancer drug development.
Drug Dev. Res. 68: 226-234, 2007.
50)  Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, Levis MJ, Neckers L, Trepel JB.
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Leukemia. 21: 2476-84, 2007.
51)  Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR, Bottaro DP.
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.
Cancer Res. 67: 6012-6, 2007.
52)  Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood. 109: 2781-90, 2007.
53)  Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clin. Cancer Res. 13: 5411-7, 2007.
54)  Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, Neckers L.
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Br. J. Cancer. 97: 741-4, 2007.
55)  Donovan EA, Kim YS, Trepel JB, Kummar S.
The use of histone deacetylase inhibitors for the treatment of solid tumors.
US Oncol Dis. 2: 12-16, 2007.
56)  Chung EJ, Lee MJ, Lee S, Trepel JB.
Assays for pharmacodynamic analysis of histone deacetylase inhibitors.
Expert Opin Drug Metab Toxicol. 2: 213-230, 2006.
57)  Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP.
c-Met ectodomain shedding rate correlates with malignant potential.
Clin. Cancer Res. 12: 4154-62, 2006.
58)  Marcu MG, Jung Y, Lee S, Chung E, Lee M, Trepel J, Neckers L.
Curcumin is an inhibitor of p300 histone acetyltransferase.
Med Chem. 2: 169-74, 2006.
59)  Niedermeier A, Talanin N, Chung EJ, Sells RE, Borris DL, Orenstein JM, Trepel JB, Blauvelt A.
Histone Deacetylase Inhibitors Induce Apoptosis with Minimal Viral Reactivation in Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus.
J Invest Dermatol. 126: 2516-24, 2006.
60)  Chang JH, Vuppalanchi D, van Niekerk E, Trepel JB, Schanen NC, Twiss JL.
PC12 cells regulate inducible cyclic AMP (cAMP) element repressor expression to differentially control cAMP response element-dependent transcription in response to nerve growth factor and cAMP.
J. Neurochem. 99: 1517-30, 2006.
61)  Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee M, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL.
A Phase II Study of Perifosine in Androgen Independent Prostate Cancer.
Cancer Biol Ther. 4: 1133-1137, 2005.
62)  Rubinstein YR, Furusawa T, Lim J, Postnikov YV, West KL, Birger Y, Lee S, Nguyen P, Trepel JB, Bustin M.
Chromosomal protein HMGN1 modulates the expression of N-cadherin.
FEBS J. 272: 5853-5863, 2005.
63)  Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability.
Cancer Cell. 8: 143-53, 2005.
64)  Chung EJ, Lee S, Sausville EA, Ryan Q, Karp JE, Gojo I, Telford WG, Lee M, Kong HS, Trepel JB.
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
Ann. Clin. Lab. Sci. 35: 397-406, 2005.
65)  Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA.
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
J Clin Oncol. 23: 3912-22, 2005.
66)  Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS.
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.
Oncogene. 24: 2386-97, 2005.
67)  Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS.
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.
Clin Cancer Res. 10: 1813-25, 2004.
68)  Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH.
Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment.
Mol Cancer Ther. 3: 1505-12, 2004.
69)  Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA.
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Mol Cancer Ther. 3: 715-25, 2004.
70)  Polzin RG, Benlhabib H, Trepel J, Herrera JE.
E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M.
Gene. 341: 209-18, 2004.
71)  Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ.
Enhanced radiation-induced cell killing and prologation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Cancer Res. 64: 316-321, 2004.
72)  Oh H, Chung E, Lee S, Loaiza-Perez A, Sausville E, Trepel J.
Targeting histone deacetylase as a strategy for cancer prevention.
Cancer Chemoprevention: Promising Cancer Chemoprevention Agents. Cancer Drug Discovery and Development. 1: 659-677, 2004.
73)  Trepel J, Birrer MJ.
A Link Between Histone Deacetylase Inhibitors and NF- kappaB Signaling.
Cell Cycle. 2: 452-3, 2003.
74)  Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, Nemieboka N, Chung EJ, Van Echo D.
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Cancer Chemother Pharmacol. 51: 439-44, 2003.
75)  Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE.
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
Carcinogenesis. 24: 453-9, 2003.
76)  Trapani V, Patel V, Leong CO, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MF, Sausville EA, Loaiza-Pérez AI.
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
Br J Cancer. 88: 599-605, 2003.
77)  Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L.
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.
Biochem J. 370: 1011-7, 2003.
78)  Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L.
IL-1beta mediated up-regulation of HIF-1alpha via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.
FASEB J. 17: 2115-2117, 2003.
79)  Trepel JB.
Ion channels as molecular targets in prostate cancer.
Clin Prostate Cancer. 2: 188-9, 2003.
80)  Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L.
Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein.
J Biol Chem. 278: 7445-52, 2003.
81)  Ochel HJ, Gademann G, Trepel J, Neckers L.
Modulation of prion protein structural integrity by geldanamycin.
Glycobiology. 13: 655-60, 2003.
82)  Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L.
The HSP90 inhibitor geldanmycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphate-dependent inactivation of AKT in ERbB2 over-expressing breast cancer cells.
Cancer Res. 63: 7777-7784, 2003.
83)  Hwang SG, Lee HC, Trepel JB, Jeon BH.
Anticancer-drug-induced apoptotic cell death in leukemia cells is associated with proteolysis of beta-catenin.
Leuk. Res. 26: 863-71, 2002.
84)  Loaiza-Pérez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MF, Bradshaw TD, Sausville EA.
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.
Mol Pharmacol. 61: 13-9, 2002.
85)  Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent S, Gardner GJ, Nguyen P, Choi YH, Trepel J, Auersperg N, Birrer MJ.
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.
Oncogene. 21: 4435-47, 2002.
86)  Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM.
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.
Cell Stress Chaperones. 7: 91-6, 2002.
87)  Chung EJ, Bonvini P, Oh H, Neckers L, Trepel J.
Nuclear beta-catenin signaling as a target for anticancer drug development.
Targets for Cancer Chemotherapy: Transcription Factors and Other Nulcear Proteins. 71-100, 2002.
88)  Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW, Henkart PA, Bottaro DP, Soon L, Bonvini P, Lee SJ, Karp JE, Oh HJ, Rubin JS, Trepel JB.
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin.
Blood. 100: 982-90, 2002.
89)  Park SH, Lee SR, Kim BC, Cho EA, Patel SP, Kang HB, Sausville EA, Nakanishi O, Trepel JB, Lee BI, Kim SJ.
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
J Biol Chem. 277: 5168-74, 2002.
90)  Mimnaugh EG, Kayastha G, McGovern NB, Hwang SG, Marcu MG, Trepel J, Cai SY, Marchesi VT, Neckers L.
Caspase-dependent deubiquitination of monoubiquitinated nucleosomal histone H2A induced by diverse apoptogenic stimuli.
Cell Death Differ. 8: 1182-96, 2001.
91)  Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP.
Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.
Oncogene. 20: 6718-23, 2001.
92)  Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL.
Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions.
FASEB J. 15: 2007-9, 2001.
93)  Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM.
Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Cancer Res. 61: 1671-7, 2001.
94)  Jhaveri MS, Wagner C, Trepel JB.
Impact of extracellular folate levels on global gene expression.
Mol. Pharmacol. 60: 1288-95, 2001.
95)  Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L.
Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Cancer Res. 61: 3750-9, 2001.
96)  Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ.
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Cancer Res. 61: 931-4, 2001.
97)  Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM.
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia. 15: 1537-43, 2001.
98)  Kim JS, Lee S, Lee T, Lee YW, Trepel JB.
Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor.
Biochem. Biophys. Res. Commun. 281: 866-71, 2001.
99)  Garayoa M, Martínez A, Lee S, Pío R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, Cuttitta F.
Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis.
Mol. Endocrinol. 14: 848-62, 2000.
100)  Kim JS, Pirnia F, Choi YH, Nguyen PM, Knepper B, Tsokos M, Schulte TW, Birrer MJ, Blagosklonny MV, Schaefer O, Mushinski JF, Trepel JB.
Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint.
Oncogene. 19: 6082-90, 2000.
101)  Bonvini P, Hwang SG, El-Gamil M, Robbins P, Kim JS, Trepel J, Neckers L.
Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells.
Biochim. Biophys. Acta. 1495: 308-18, 2000.
102)  Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, Trepel J, Reed E, Neckers L.
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Biochem. Pharmacol. 60: 1343-54, 2000.
103)  An WG, Hwang SG, Trepel JB, Blagosklonny MV.
Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
Leukemia. 14: 1276-83, 2000.
104)  Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO.
The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties.
J. Biol. Chem. 275: 3305-12, 2000.
105)  Lee J, Choi YH, Nguyen P, Kim JS, Lee SJ, Trepel JB.
Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells.
Biochim. Biophys. Acta. 1449: 261-8, 1999.
106)  Bonvini P, Hwang SG, el-Gamil M, Robbins P, Neckers L, Trepel J.
Melanoma cell lines contain a proteasome-sensitive, nuclear cytoskeleton-associated pool of beta-catenin.
Ann. N. Y. Acad. Sci. 886: 208-11, 1999.
107)  Jang JS, Lee SJ, Choi YH, Nguyen PM, Lee J, Hwang SG, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB.
Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease.
Oncogene. 18: 1789-96, 1999.
108)  Romanova LY, Alexandrov IA, Blagosklonny MV, Nordan RP, Garfield S, Acs P, Nguyen P, Trepel J, Blumberg PM, Mushinski JF.
Regulation of actin cytoskeleton in lymphocytes: PKC-delta disrupts IL-3-induced membrane ruffles downstream of Rac1.
J. Cell. Physiol. 179: 157-69, 1999.
109)  Blagosklonny MV, An WG, Melillo G, Nguyen P, Trepel JB, Neckers LM.
Regulation of BRCA1 by protein degradation.
Oncogene. 18: 6460-8, 1999.
110)  Ochel HJ, Schulte TW, Nguyen P, Trepel J, Neckers L.
The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase.
Mol. Genet. Metab. 66: 24-30, 1999.
111)  Yang HK, Scott FM, Trepel JB, Battey JF, Johnson BE, Kelley MJ.
Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines.
Lung Cancer. 21: 165-75, 1998.
112)  Bonvini P, Nguyen P, Trepel J, Neckers LM.
In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome.
Oncogene. 16: 1131-9, 1998.
113)  Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB.
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
J. Biol. Chem. 273: 10618-23, 1998.
114)  Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L.
p53 inhibits hypoxia-inducible factor-stimulated transcription.
J. Biol. Chem. 273: 11995-8, 1998.
115)  Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC.
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1).
Prostate. 37: 51-9, 1998.
116)  Kim M, Katayose Y, Li Q, Rakkar AN, Li Z, Hwang SG, Katayose D, Trepel J, Cowan KH, Seth P.
Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1.
Biochem. Biophys. Res. Commun. 253: 672-7, 1998.
117)  Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P.
A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells.
Oncogene. 14: 2283-9, 1997.
118)  Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB.
Regulation of cyclin D1 by calpain protease.
J. Biol. Chem. 272: 28479-84, 1997.
119)  Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM.
Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.
Mol. Cell. Biol. 16: 5839-45, 1996.
120)  Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L.
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
Clin. Exp. Metastasis. 14: 389-98, 1996.
121)  Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L.
p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.
J. Biol. Chem. 271: 4974-7, 1996.
122)  Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE.
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Clin. Cancer Res. 2: 483-91, 1996.
123)  Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM.
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.
Cancer Res. 56: 1851-4, 1996.
124)  Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E.
Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3.
Cancer Res. 55: 2122-8, 1995.
125)  Bergsagel PL, Brents LA, Trepel JB, Kuehl WM.
Genes expressed selectively in murine and human plasma cell neoplasms.
Curr. Top. Microbiol. Immunol. 194: 57-61, 1995.
126)  Chung KN, Roberts S, Kim CH, Kirassova M, Trepel J, Elwood PC.
Rapid turnover and impaired cell-surface expression of the human folate receptor in mouse L(tk-) fibroblasts, a cell line defective in glycosylphosphatidylinositol tail synthesis.
Arch. Biochem. Biophys. 322: 228-34, 1995.
127)  Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L.
Taxol induction of p21WAF1 and p53 requires c-raf-1.
Cancer Res. 55: 4623-6, 1995.
128)  Ben-Baruch N, Reinhold WC, Alexandrova N, Ichinose I, Blake M, Trepel JB, Zajac-Kaye M.
c-myc Down-regulation in suramin-treated HL60 cells precedes growth inhibition but does not trigger differentiation.
Mol. Pharmacol. 46: 73-8, 1994.
129)  Grem JL, Daychild P, Drake J, Geoffroy F, Trepel JB, Pirnia F, Allegra CJ.
Cytotoxicity and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells.
Biochem. Pharmacol. 48: 2117-26, 1994.
130)  Gudas JM, Oka M, Diella F, Trepel J, Cowan KH.
Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells.
Cell Growth Differ. 5: 295-304, 1994.
131)  Chung KN, Paik TH, Roberts S, Kim CH, Kirassova M, Weinstein JN, Trepel JB, Elwood PC.
Site-directed mutagenesis of tryptophan residues to conserved hydrophobic residues inhibits the processing of human KB cell folate receptor.
Arch. Biochem. Biophys. 315: 407-14, 1994.
132)  Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB.
Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.
Proc. Natl. Acad. Sci. U.S.A. 91: 5330-4, 1994.
133)  Borner MM, Schneider E, Pirnia F, Sartor O, Trepel JB, Myers CE.
The detergent Triton X-100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte-induced apoptosis.
FEBS Lett. 353: 129-32, 1994.
134)  Myers C, Trepel J, Sartor O, Cooper M, Ranson M, Toko T, Linehan MW.
Antigrowth factor strategies.
Cancer. 71: 1172-8, 1993.
135)  Fang F, Ahmad S, Lei J, Klecker RW, Trepel JB, Smithgall TE, Glazer RI.
Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.
Biochemistry. 32: 6995-7001, 1993.
136)  Schlaifer D, Cooper MR, Attal M, Sartor AO, Trepel JB, Laurent G, Myers CE.
Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia.
Blood. 81: 482-9, 1993.
137)  Bergsagel PL, Victor-Kobrin C, Timblin CR, Trepel J, Kuehl WM.
A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells.
J. Immunol. 148: 590-6, 1992.
138)  Bang YJ, Kim SJ, Danielpour D, O'Reilly MA, Kim KY, Myers CE, Trepel JB.
Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3.
Proc. Natl. Acad. Sci. U.S.A. 89: 3556-60, 1992.
139)  Johnston PG, Drake JC, Trepel J, Allegra CJ.
Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Cancer Res. 52: 4306-12, 1992.
140)  Yee LK, Allegra CJ, Trepel JB, Grem JL.
Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells.
Biochem. Pharmacol. 43: 1587-99, 1992.
141)  Fang WG, Pirnia F, Bang YJ, Myers CE, Trepel JB.
P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells.
J. Clin. Invest. 89: 191-6, 1992.
142)  Ahmad S, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Glazer RI.
Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin.
Mol. Pharmacol. 42: 1004-9, 1992.
143)  Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT.
Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines.
J. Natl. Cancer Inst. 84: 711-6, 1992.
144)  Dixon KH, Trepel JB, Eng SC, Cowan KH.
Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
Cancer Commun. 3: 357-65, 1991.
145)  Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH, Glazer RI.
Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein.
Cancer Commun. 3: 181-9, 1991.
146)  Graham SJ, Duval-Arnould B, Mercado TC, Trepel JB, Cotelingam JD.
Burkitt's lymphoma: a pericardial presentation.
Cytopathology. 1: 239-42, 1990.
147)  Park JG, Frucht H, LaRocca RV, Bliss DP, Kurita Y, Chen TR, Henslee JG, Trepel JB, Jensen RT, Johnson BE.
Characteristics of cell lines established from human gastric carcinoma.
Cancer Res. 50: 2773-80, 1990.
148)  Sharoni Y, Viallet J, Trepel JB, Sausville EA.
Effect of guanine and adenine nucleotides on bombesin-stimulated phospholipase C activity in membranes from Swiss 3T3 and small cell lung carcinoma cells.
Cancer Res. 50: 5257-62, 1990.
149)  Sausville EA, Trepel JB, Moyer JD.
Inhibitors of bombesin-stimulated intracellular signals: interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma.
Prog. Clin. Biol. Res. 354A: 193-207, 1990.
150)  Mulshine JL, Natale RB, Avis I, Treston AM, Kasprzyk PG, Nakanishi Y, Sausville EA, Trepel JB, Cuttitta F.
Autocrine growth factors and lung cancer.
Cancer Treat. Res. 45: 107-22, 1989.
151)  Rosolen A, Nakanishi M, Poplack DG, Cole D, Quinones R, Reaman G, Trepel JB, Cotelingam JD, Sausville EA, Marti GE.
Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies.
Blood. 73: 1968-72, 1989.
152)  Sausville EA, Moyer JD, Heikkila R, Neckers LM, Trepel JB.
A correlation of bombesin-responsiveness with myc-family gene expression in small cell lung carcinoma cell lines.
Ann. N. Y. Acad. Sci. 547: 310-21, 1988.
153)  Trepel JB, Moyer JD, Cuttitta F, Frucht H, Coy DH, Natale RB, Mulshine JL, Jensen RT, Sausville EA.
A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line.
Biochem. Biophys. Res. Commun. 156: 1383-9, 1988.
154)  Minna JD, Cuttitta F, Battey JF, Mulshine JL, Linnoila I, Gazdar AF, Trepel J, Sausville EA.
Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications.
Important Adv. Oncol. 55-64, 1988.
155)  Vidal C, Matsushita S, Colamonici OR, Trepel JB, Mitsuya H, Neckers LM.
Human T lymphotropic virus I infection deregulates surface expression of the transferrin receptor.
J. Immunol. 141: 984-8, 1988.
156)  Trepel JB, Moyer JD, Heikkila R, Sausville EA.
Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small-cell lung-cancer cell line.
Biochem. J. 255: 403-10, 1988.
157)  Colamonici OR, Quinones R, Rosolen A, Trepel JB, Sausville E, Phares JC, Gress R, Poplack D, Weber J, Schechter GP.
The beta subunit of the interleukin-2 receptor mediates interleukin-2 induction of anti-CD3 redirected cytotoxic capability in large granular lymphocytes.
Blood. 71: 825-8, 1988.
158)  Heikkila R, Trepel JB, Cuttitta F, Neckers LM, Sausville EA.
Bombesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines.
J. Biol. Chem. 262: 16456-60, 1987.
159)  Trepel JB, Colamonici OR, Kelly K, Schwab G, Watt RA, Sausville EA, Jaffe ES, Neckers LM.
Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells.
Mol. Cell. Biol. 7: 2644-8, 1987.
160)  Neckers LM, Bauer S, McGlennen RC, Trepel JB, Rao K, Greene WC.
Diltiazem inhibits transferrin receptor expression and causes G1 arrest in normal and neoplastic T cells.
Mol. Cell. Biol. 6: 4244-50, 1986.
161)  Matsushita S, Robert-Guroff M, Trepel J, Cossman J, Mitsuya H, Broder S.
Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I.
Proc. Natl. Acad. Sci. U.S.A. 83: 2672-6, 1986.
162)  Colamonici OR, Trepel JB, Neckers LM.
Megakaryocyte differentiation: studies at the molecular level using the K-562 cell line.
Prog. Clin. Biol. Res. 215: 187-91, 1986.
163)  Colamonici OR, Trepel JB, Vidal CA, Neckers LM.
Phorbol ester induces c-sis gene transcription in stem cell line K-562.
Mol. Cell. Biol. 6: 1847-50, 1986.
164)  Neckers LM, Trepel JB.
Transferrin receptor expression and the control of cell growth.
Cancer Invest. 4: 461-70, 1986.
165)  Colamonici OR, Trepel JB, Neckers LM.
Phorbol ester enhances deoxynucleoside incorporation while inhibiting proliferation of K-562 cells.
Cytometry. 6: 591-6, 1985.
166)  Neckers LM, Funkhouser WK, Trepel JB, Cossman J, Gratzner HG.
Significant non-S-phase DNA synthesis visualized by flow cytometry in activated and in malignant human lymphoid cells.
Exp. Cell Res. 156: 429-38, 1985.
167)  Neckers LM, Yenokida G, Trepel JB, Lipford E, James S.
Transferrin receptor induction is required for human B-lymphocyte activation but not for immunoglobulin secretion.
J. Cell. Biochem. 27: 377-89, 1985.
168)  Cossman J, Neckers LM, Braziel RM, Trepel JB, Korsmeyer SJ, Bakhshi A.
In vitro enhancement of immunoglobulin gene expression in chronic lymphocytic leukemia.
J. Clin. Invest. 73: 587-92, 1984.
169)  Cooper HL, Fagnani R, London J, Trepel J, Lester EP.
Effect of interferons on protein synthesis in human lymphocytes: enhanced synthesis of eight specific peptides in T cells and activation-dependent inhibition of overall protein synthesis.
J. Immunol. 128: 828-33, 1982.
170)  Goodman SI, Wyatt RJ, Trepel JB, Neckers LM.
NAD glycohydrolase: enzyme characterization using intact mammalian erythrocytes.
Comp. Biochem. Physiol., B. 71: 333-6, 1982.
171)  Trepel JB, Chuang DM, Neff NH.
Polypeptide hormones and chromatin-associated proteins act as acceptors for cholera toxin-catalyzed ADP-ribosylation.
J. Neurochem. 36: 538-43, 1981.
172)  Rohwer RG, Neckers LM, Trepel JB, Gajdusek DC, Wyatt RJ.
Serotonin concentrations in brain and blood of scrapie-infected and normal hamsters and mice.
Brain Res. 220: 367-71, 1981.
173)  Trepel JB, Wyatt RJ, Neff NH.
Differential distribution of type A and B monoamine oxidase in neuronal tissues.
Eur. J. Pharmacol. 43: 373-5, 1977.
174)  Fuentes JA, Trepel JB, Neff NH.
Monoamine oxidase activity in the cardiovascular system of young and aged rats.
Exp. Gerontol. 12: 113-5, 1977.
175)  Trepel JB, Chuang DM, Neff NH.
Transfer of ADP-ribose from NAD to choleragen: a subunit acts as catalyst and acceptor protein.
Proc. Natl. Acad. Sci. U.S.A. 74: 5440-2, 1977.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/1/2014.